Atopic Dermatitis

Experts on atopic dermatitis compare the safety profile of JAK inhibitors with traditional and more advanced treatments currently available for patients.

Nemolizumab shows early and sustained benefits in reducing itch and sleep disturbance in moderate-to-severe atopic dermatitis, per ARCADIA data.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

This is an overview of our upcoming Maui Derm NP+PA Fall 2024 Program conference coverage.

Eli Lilly’s announcement of the lebrikizumab-lbkz approval for patients 12 years of age and older follows positive findings from the ADvocate 1, ADvocate 2, and ADhere studies.

Multiple biomarkers and clinical background factors were linked to improved clinical outcomes after dupilumab therapy for AD.

In this analysis, an increased risk of allergy and eczema was associated with bread and thiamine intake increases during pregnancy.

In this survey, investigators sought to develop a definition for eczema flare which was patient-centered and based upon consensus.

These data may provide invaluable insights, given the lack of reliable methods for identifying newborns with increased risk of developing eczema.

These findings resulted from a systematic literature review highlighting the impact of stigma and lack of support on self-image for patients with eczema, psoriasis, HS, and other conditions.

A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms.

Focusing on the complex pathophysiology of atopic dermatitis, Lindsay S. Ackerman, MD, FAAD, discusses the importance of looking beyond type 2 inflammation while treating patients.

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.

After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.

These data were presented at the European Society of Contact Dermatitis congress, with findings drawn from the CHECK and RWEAL studies on chronic hand eczema.

Dermatologists outline unmet needs in the treatment landscape for atopic dermatitis and discuss how to potentially improve the standard of care for patients with atopic dermatitis.

The panel provides comprehensive insights on treating atopic dermatitis and how recent advances have elevated standard-of-care treatment practices in dermatology practices.

These data suggest the necessity of caution when clinicians treat select patient groups with dupilumab for atopic dermatitis.

These data are encouraging for tralokinumab, though additional observational research with more individuals with atopic dermatitis or longer follow-up periods may be necessary.

These data reaffirm NB-UVB phototherapy’s use in treating patients with atopic dermatitis and psoriasis, suggesting improvement in patient-reported outcome measures.

This analysis was conducted to evaluate the efficacy and safety results of AIT for patients with house dust mite allergies.

A panel of experts on atopic dermatitis discuss how patient preferences are taken into account when choosing between available treatments.

Jonathan Silverberg, MD, PhD, MPH, offers insights on the role of patient-reported outcomes in informing treatment decisions for patients with atopic dermatitis.

A new study revealed children who go from normal weight to overweight have a greater risk of atopic dermatitis than obese children who maintain their weight.